biological source
sheep
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunodiffusion: suitable, immunohistochemistry: suitable, western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... UMOD(7369)
Immunogen
Highly purified human Tamm-Horsfall glycoprotein (uromucoid) from urine; >95% pure by SDS-PAGE.
Application
IEP: 100 μL antiserum vs. 5 μL uromucoid (50 mg/L)
RID and Rocket RID: 10 μL antiserum/cm2 in gel vs. 5 μL uromucoid (50 mg/L), NT - 1/5
Double diffusion: 10 μL antiserum vs. 3 μL uromucoid (50 mg/L)
*Note: The use of 3% PEG 6000 with 1.2% agarose in a suitable buffer (such as TBE or Tris-barbital pH >8.2) is recommended for the above applications.
Immunohistochemistry
Optimal working dilution must be determined by the end user.
RID and Rocket RID: 10 μL antiserum/cm2 in gel vs. 5 μL uromucoid (50 mg/L), NT - 1/5
Double diffusion: 10 μL antiserum vs. 3 μL uromucoid (50 mg/L)
*Note: The use of 3% PEG 6000 with 1.2% agarose in a suitable buffer (such as TBE or Tris-barbital pH >8.2) is recommended for the above applications.
Immunohistochemistry
Optimal working dilution must be determined by the end user.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
Immunoglobulins & Immunology
This Anti-Tamm-Horsfall Glycoprotein Antibody is validated for use in ID, WB, IH for the detection of Tamm-Horsfall Glycoprotein.
Biochem/physiol Actions
One arc by 2D-IEP against Tamm-Horsfall glycoprotein (1 mg/mL). No precipitin line by IEP against normal human plasma. Identity verified by double immunodiffusion.
Physical form
In glycine buffered saline, pH 7.4 containing 0.1% sodium azide, 0.1% E-Amino-n-Caproic Acid, 0.01% Benzamidine and 1 mM Ethylenediaminetetraacetic acid as preservatives.
Preparation Note
Maintain at 2-8°C in undiluted aliquots for up to 12 months.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Fernanda Chacar et al.
Physiological reports, 5(11) (2017-06-04)
Proteinuria is a marker and mediator of chronic kidney disease (CKD). In clinical practice, the urinary protein-to-creatinine ratio (UP/C) is of limited usefulness, because it indicates only the magnitude of proteinuria and not the origin of the loss (glomerular or
Shinji Sasaki et al.
BMC genomics, 17(1), 724-724 (2016-09-11)
Hydrallantois is the excessive accumulation of fluid within the allantoic cavity in pregnant animals and is associated with fetal mortality. Although the incidence of hydrallantois is very low in artificial insemination breeding programs in cattle, recently 38 cows with the
Jenni Karttunen et al.
International journal of molecular sciences, 22(9) (2021-06-03)
Urinary extracellular vesicles (EVs) and their RNA cargo are a novel source of biomarkers for various diseases. We aimed to identify the optimal method for isolating small (<200 nm) EVs from human urine prior to small RNA analysis. EVs from
Brian M Nolen et al.
PloS one, 8(5), e63368-e63368 (2013-06-01)
The analysis of protein biomarkers in urine is expected to lead to advances in a variety of clinical settings. Several characteristics of urine including a low-protein matrix, ease of testing and a demonstrated proteomic stability offer distinct advantages over current
Jean-Claude Kresse et al.
Acta physiologica (Oxford, England), 234(3), e13780-e13780 (2022-01-07)
Renal fibrosis is a major driver of chronic kidney disease, yet current treatment strategies are ineffective in attenuating fibrogenesis. The cyclooxygenase/prostaglandin system plays a key role in renal injury and holds great promise as a therapeutic target. Here, we used
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持